BLEXTEN SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

BILASTINE

थमां उपलब्ध:

ARALEZ PHARMACEUTICALS CANADA INC

ए.टी.सी कोड:

R06AX29

INN (इंटरनेशनल नाम):

BILASTINE

डोज़:

2.5MG

फार्मास्यूटिकल फॉर्म:

SOLUTION

रचना:

BILASTINE 2.5MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

15G/50G

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

SECOND GENERATION ANTIHISTAMINES

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0158051002; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2021-08-11

उत्पाद विशेषताएं

                                _BLEXTEN_
_® _
_Product Monograph _
_ _
_Page 1 of 41_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
BLEXTEN
®
(bilastine)
Orodispersible tablets 10 mg
Tablets 20 mg
Oral solution 2.5 mg/mL
Histamine H1-Receptor Antagonist
Aralez Pharmaceuticals Canada Inc.*
6733 Mississauga Road, Suite 800
Mississauga, Ontario
Canada L5N 6J5
Date of Initial Approval:
April 20, 2016
Date of Revision:
August 10, 2021
Submission Control No:
241318
*Doing business as (d/b/a) Miravo Healthcare
_ _
_BLEXTEN_
_®_
_ Product Monograph _
_ _
_Page 2 of 41_
TABLE OF CONTENTS
Sections or subsections that are not applicable at the time of
authorization are not listed.
TABLE OF
CONTENTS.......................................................................................................
2
1
INDICATIONS
...........................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics
..........................................................................................................
4
2
CONTRAINDICATIONS
...........................................................................................
4
4
DOSAGE AND ADMINISTRATION
.........................................................................
4
4.1
Dosing
Considerations.....................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
.............................................. 5
4.4
Administration...................................................................................................
5
4.5
Missed
Dose.....................................................................................................
6
5
OVERDOSAGE
.........................................................................................................
6
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .............. 7
7
WARNINGS AND
PRECAUTIONS.......
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 10-08-2021

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें